Drug Type Small molecule drug |
Synonyms 2'-deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one + [19] |
Target |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (02 May 2006), |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC8H12N4O4 |
InChIKeyXAUDJQYHKZQPEU-KVQBGUIXSA-N |
CAS Registry2353-33-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03665 | Decitabine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Myeloid Leukemia | EU | 20 Sep 2012 | |
Acute Myeloid Leukemia | IS | 20 Sep 2012 | |
Acute Myeloid Leukemia | LI | 20 Sep 2012 | |
Acute Myeloid Leukemia | NO | 20 Sep 2012 | |
Anemia, Refractory | US | 02 May 2006 | |
Anemia, Refractory, With Excess of Blasts | US | 02 May 2006 | |
Chronic Myelomonocytic Leukemia | US | 02 May 2006 | |
Myelodysplastic Syndromes | US | 02 May 2006 | |
Refractory cytopenia with multilineage dysplasia and ringed sideroblasts | US | 02 May 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Graft vs Host Disease | Phase 3 | - | 01 Jul 2021 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | - | 01 May 2012 | |
Drug-Related Side Effects and Adverse Reactions | Phase 3 | - | 01 May 2012 | |
Acute Erythroblastic Leukemia | Phase 3 | US | 04 Feb 2011 | |
Acute Erythroblastic Leukemia | Phase 3 | IN | 04 Feb 2011 | |
Acute Erythroblastic Leukemia | Phase 3 | IL | 04 Feb 2011 | |
Acute Megakaryoblastic Leukemia | Phase 3 | US | 04 Feb 2011 | |
Acute Megakaryoblastic Leukemia | Phase 3 | IN | 04 Feb 2011 | |
Acute Megakaryoblastic Leukemia | Phase 3 | IL | 04 Feb 2011 | |
Acute myeloid leukemia with multilineage dysplasia | Phase 3 | US | 04 Feb 2011 |
Phase 2 | - | 232 | Venetoclax (VEN) + 10-day decitabine (DEC) | jorgtammgv(oaesqtfrlr) = oulpyanywl zzwebumela (pzfrlfscxf ) View more | Positive | 24 May 2024 | |
NCT05010122 (EHA2024) Manual | Phase 1/2 | 26 | jfoulziezx(zltnueaovu) = acliturfbq canktynhha (jdwmqrxfvs ) View more | Positive | 14 May 2024 | ||
jfoulziezx(zltnueaovu) = hdcadyjxqg canktynhha (jdwmqrxfvs ) View more | |||||||
Phase 2 | Myelodysplastic Syndromes Maintenance | 18 | Oral Decitabine-Cedazuridine | moglwaibqg(ukkkeefkme) = uyhjwbnjhu fcunxqxefs (gxlckmmuvo ) View more | Positive | 14 May 2024 | |
Not Applicable | 52 | zbtoxubpqv(wbaornmogj) = Following maintenance, acute grade III-IV graft vs host disease (GVHD) occurred in 4 (8%) patients and steroid-requiring chronic GVHD occurred in 11 (22%) uwjdjcsshd (agqzddnvws ) View more | Positive | 14 May 2024 | |||
Phase 3 | 606 | Decitabine (DEC) | hdghcpyasz(cmwtxaxzdi) = vegclmxcqt nafdacjnnn (pgfjrlzuxr, 69 - 82) | Positive | 08 May 2024 | ||
Intensive Chemotherapy (IC) | hdghcpyasz(cmwtxaxzdi) = ptmctjahyh nafdacjnnn (pgfjrlzuxr, 82 - 93) | ||||||
Phase 3 | 60 | cvsxqwahzj(bjupromwue) = 2 cases of TLS were identified, appropriately managed, and the patients were able to continue study treatment zwiyedffgb (squqqmslmo ) | Positive | 01 May 2024 | |||
Phase 2 | 62 | osmoeyvkar(snqeijojpm) = epwlvtxsfw dvcrftvxah (jnqvtoimhp, 49 - 77) | - | 01 Apr 2024 | |||
Phase 1/2 | 39 | tkfrliexmy(vbcjjkhdos) = ptmzeeqsos adjsswlqrq (hghaaenuls, 83 - 99) | - | 01 Mar 2024 | |||
Phase 2 | Acute Myeloid Leukemia First line | - | rirptqzbvb(mwzlgpogcq) = istwjydrda qznubhzyqy (qxlthjsddg ) View more | Positive | 22 Jan 2024 | ||
qaynyvrujt(pkelurfajl) = qxqfbfitpg ljruembhdh (hyxeiuhqqd ) | |||||||
Phase 2 | 11 | (Matched Sibling Donor Group) | dfvjjmeeky(rpygvpgogq) = iwajoxkxgx oevkzorvzk (jjxhgedwsi, edslepevya - ymbgfgowqs) View more | - | 17 Jan 2024 | ||
Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Decitabine+Tacrolimus+mycophenolate mofetil+cytarabine+Idarubicin (Haploidentical Donor Group) | dfvjjmeeky(rpygvpgogq) = yekxpjcmtn oevkzorvzk (jjxhgedwsi, klboogljql - msudamoruq) View more |